CTMX
NASDAQ · Biotechnology
Cytomx Therapeutics Inc
$2.19
+0.05 (+2.34%)
Financial Highlights (FY 2026)
Revenue
122.29M
Net Income
-27,871,952
Gross Margin
—
Profit Margin
-22.8%
Rev Growth
+12.7%
D/E Ratio
—
Revenue & Net Income
Margin Trends
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Gross Margin | — | — | 45.0% | 45.0% |
| Operating Margin | -29.3% | -26.4% | 14.3% | 15.7% |
| Profit Margin | -22.8% | -21.7% | 12.8% | 9.4% |
Income Statement
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Revenue | 122.29M | 108.49M | 145.29M | 120.96M |
| Gross Profit | — | — | 65.37M | 54.42M |
| Operating Income | -35,892,478 | -28,657,940 | 20.81M | 19.03M |
| Net Income | -27,871,952 | -22,254,042 | 18.60M | 11.33M |
| Gross Margin | — | — | 45.0% | 45.0% |
| Operating Margin | -29.3% | -26.4% | 14.3% | 15.7% |
| Profit Margin | -22.8% | -21.7% | 12.8% | 9.4% |
| Rev Growth | +12.7% | +12.7% | +5.8% | -7.0% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Total Debt | 0 | 0 | 261.90M | 281.15M |
| Total Equity | — | — | 637.36M | 662.84M |
| D/E Ratio | — | — | 0.41 | 0.42 |
Cash Flow
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| EBITDA | -33,915,672 | -28,584,003 | 25.56M | 23.91M |
| Free Cash Flow | — | — | 18.27M | 13.74M |